BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25326682)

  • 1. Hypoxia-inducible factors enhance glutamate signaling in cancer cells.
    Hu H; Takano N; Xiang L; Gilkes DM; Luo W; Semenza GL
    Oncotarget; 2014 Oct; 5(19):8853-68. PubMed ID: 25326682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
    Carroll VA; Ashcroft M
    Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer.
    Grampp S; Platt JL; Lauer V; Salama R; Kranz F; Neumann VK; Wach S; Stöhr C; Hartmann A; Eckardt KU; Ratcliffe PJ; Mole DR; Schödel J
    Nat Commun; 2016 Oct; 7():13183. PubMed ID: 27774982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factors in the kidney.
    Haase VH
    Am J Physiol Renal Physiol; 2006 Aug; 291(2):F271-81. PubMed ID: 16554418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIFing the brakes: therapeutic opportunities for treatment of human malignancies.
    Garcia JA
    Sci STKE; 2006 May; 2006(337):pe25. PubMed ID: 16738063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
    Petrella BL; Brinckerhoff CE
    Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals.
    Wu TK; Wei CW; Pan YR; Hsu RJ; Wu CY; Yu YL
    Sci Rep; 2019 Mar; 9(1):3207. PubMed ID: 30824757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma.
    Wright TM; Rathmell WK
    J Biol Chem; 2010 Apr; 285(17):12916-24. PubMed ID: 20185829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells.
    Razorenova OV; Castellini L; Colavitti R; Edgington LE; Nicolau M; Huang X; Bedogni B; Mills EM; Bogyo M; Giaccia AJ
    Mol Cell Biol; 2014 Feb; 34(4):739-51. PubMed ID: 24344197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.
    Zhai W; Sun Y; Jiang M; Wang M; Gasiewicz TA; Zheng J; Chang C
    Oncogene; 2016 Sep; 35(37):4866-80. PubMed ID: 26973243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
    Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
    J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.
    Zhang ZY; Zhang SL; Chen HL; Mao YQ; Li ZM; Kong CY; Han B; Zhang J; Chen YH; Xue W; Zhai W; Wang LS
    Cell Prolif; 2020 Jul; 53(7):e12853. PubMed ID: 32537867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
    Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
    Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anterior gradient 2 promotes tumorigenesis through upregulation of CCAAT-enhancer binding protein beta and hypoxia-inducible factor-2α and subsequent secretion of interleukin-6, interleukin-8, and vascular endothelial growth factor in the Caki-1 clear cell renal cell carcinoma cell line.
    Pajdzik K; Wilamowski M; Żurawek D; Stopa KB; Nodzyński M; Kalita A; Jura J
    IUBMB Life; 2020 Aug; 72(8):1807-1818. PubMed ID: 32593213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.
    Elorza A; Soro-Arnáiz I; Meléndez-Rodríguez F; Rodríguez-Vaello V; Marsboom G; de Cárcer G; Acosta-Iborra B; Albacete-Albacete L; Ordóñez A; Serrano-Oviedo L; Giménez-Bachs JM; Vara-Vega A; Salinas A; Sánchez-Prieto R; Martín del Río R; Sánchez-Madrid F; Malumbres M; Landázuri MO; Aragonés J
    Mol Cell; 2012 Dec; 48(5):681-91. PubMed ID: 23103253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice.
    Wang J; Ma Y; Jiang H; Zhu H; Liu L; Sun B; Pan S; Krissansen GW; Sun X
    J Hepatol; 2011 Aug; 55(2):359-68. PubMed ID: 21168458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.